The EMA, following on from the FDA’s lead earlier this month, has announced that it will revise its guidelines on clinical trial studies for the treatment of Alzheimer’s disease from 1 September 2018 onwards.
The move is remarkably similar to the FDA’s move, in that it will allow for clinical trials to be focused at an earlier point disease-progression point – in some cases, before clinical symptoms have become discernible.
